Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:58:11 EDT Mon 07 Oct 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:VRNA - VERONA PHARMA SPON ADR EACH REP 8 ORD SHS - https://www.veronapharma.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRNA - Q0.131.13·32.882.132.05+0.040.11,026.032,5087,88432.17  32.81  31.440132.88  11.39519:22:36Sep 3015 min RT 2¢

Recent Trades - Last 10 of 7884
Time ETExPriceChangeVolume
19:22:36Q31.41-0.6010
19:22:36Q31.41-0.60100
19:22:36Q31.39-0.62125
19:22:36Q31.38-0.6379
19:22:36Q31.38-0.6376
19:22:36Q31.38-0.6310
19:17:37Q31.56-0.4510
18:32:27Q31.56-0.453
17:08:15Q32.050.043,714
16:11:33Q31.27-0.741

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-30 02:00U:VRNANews ReleaseVerona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
2024-09-05 02:00U:VRNANews ReleaseVerona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
2024-08-08 02:00U:VRNANews ReleaseVerona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-07-30 02:00U:VRNANews ReleaseVerona Pharma to Present at 44th Annual Canaccord Growth Conference
2024-07-25 02:00U:VRNANews ReleaseVerona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
2024-06-26 16:57U:VRNANews ReleaseVerona Pharma Announces US FDA Approval of Ohtuvayre(TM) (ensifentrine)
2024-05-09 07:15U:VRNANews ReleaseVerona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-09 07:00U:VRNANews ReleaseVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
2024-05-02 02:00U:VRNANews ReleaseVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
2024-04-25 02:00U:VRNANews ReleaseVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
2024-03-04 02:00U:VRNANews ReleaseAndrew Fisher Joins Verona Pharma as General Counsel
2024-02-29 02:00U:VRNANews ReleaseVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-15 02:00U:VRNANews ReleaseVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
2024-02-01 02:00U:VRNANews ReleaseMichael Austwick Joins Verona Pharma as Non-Executive Director
2024-01-03 02:00U:VRNANews ReleaseVerona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 02:00U:VRNANews ReleaseVerona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
2023-11-17 02:00U:VRNANews ReleaseVerona Pharma ¢ € ™s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
2023-11-08 02:00U:VRNANews ReleaseVerona Pharma Announces November 2023 Investor Conference Participation
2023-11-02 03:04U:VRNANews ReleaseVerona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-19 02:00U:VRNANews ReleaseVerona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update